TABLE 3.
Analytical framework of the sample of reviewed empirical articles.
| No. of article | Frame of the scientific visibility and institutional backing |
Multidimensional classification of structural components |
||||||
| No. of quotations | Impact factor | Country | Field of knowledge | Perspective | Guiding aim | Type of study | Results | |
| 1 | 78 | 0.70/Q4 | USA | CEX | ACT | DIS | QUAN | FOR |
| 2 | 77 | – | USA | CEX | COG | REN | QUAN | TEC |
| 3 | 73 | 1.394/Q1 | Spain | SOC | COM | DIS | QUAN | TEC |
| 4 | 53 | – | USA | SOC | COG | INS REN | QUAN | FOR |
| 5 | 52 | – | Finland | CEX | COM | REN | MM | TEC |
| 6 | 48 | 0.667/Q3 | USA | SOC | COM | DIS REN | QUAN | TEC CRI |
| 7 | 34 | – | USA | SOC | COM | REN | QUAN | FOR |
| 8 | 26 | – | USA | SOC | COM | REN | QUAN | FOR |
| 9 | 23 | 1.302/Q1 | Belgium | SOC | ACT | DIS | QUAN | FOR |
| 10 | 20 | – | Sri Lanka | DIV | COM | INS DIS | MM | FOR |
| 11 | 20 | – | Iran | CEX | COM | REN | QUAN | FOR TEC |
| 12 | 19 | – | Turkey | MED | COG | REN | QUAN | FOR TEC |
| 13 | 19 | – | India | MED | ACT | REN | QUAN | FOR TEC |
| 14 | 18 | 5.627/Q1 | South Korea | SOC | COG | REN | QUAN | FOR TEC |
| 15 | 16 | – | Indonesia | BIO | ACT | REN | QUAN | FOR |
| 16 | 15 | – | Denmark | CEX | COM | REN | QUAN | TEC |
| 17 | 15 | – | USA | SOC | ACT | DIS | QUAN | FOR |
| 18 | 12 | – | USA | EAD | COG | REN | QUAN | FOR TEC |
| 19 | 11 | – | USA | MED | COM | DIS REN | QUAN | CRI |
| 20 | 11 | – | Russia/Israel | DIV | COM | DIS | QUAN | TEC |
| 21 | 10 | – | China | MED | COM | REN | QUAN | FOR |
| 22 | 10 | – | Australia | DIV | COM | DIS | QUAN | FOR TEC |
| 23 | 9 | – | Iran | CEX | COM | REN | QUAN | CRI |
| 24 | 9 | Q2 | South Africa | HUM | COG | REN | QUAN | FOR TEC |
| 25 | 9 | – | Zimbabwe | DIV | COM | DIS | QUAN | TEC |
| 26 | 8 | 3.759/Q1 | India | MED | COG | DIS REN | QUAN | FOR |
| 27 | 8 | – | Malaysia | HUM | COM | INS | QUAN | FOR |
| 28 | 7 | 2.297/Q1 | South Korea | HUM | COG | REN | QUAN | FOR TEC |
| 29 | 7 | – | USA | CEX | ACT | DIS REN | QUAN | CRI |
| 30 | 6 | – | USA | SOC | COG | REN | QUAN | FOR |
| 31 | 5 | – | Poland/ Ukraine |
SOC | COM | DIS REN | QUAN | FOR TEC |
| 32 | 4 | Q3 | Iran | MED | COG | REN | QUAN | CRI |
| 33 | 4 | – | USA | CEX | COG | REN | QUAN | FOR |
| 34 | 4 | – | USA | EAD | ACT | INS | QUAN | FOR |
| 35 | 3 | 0.7/Q2 | Spain | EAD | COM | INS | QUAN | FOR |
| 36 | 3 | – | China | HUM | COM | REN | QUAN | FOR TEC |
| 37 | 3 | – | Spain | EAD | COM | INS | QUAN | FOR |
| 38 | 2 | – | USA | MED | ACT | REN | QUAN | FOR TEC |
| 39 | 2 | – | Indonesia | SOC | COM | REN | QUAN | CRI |
| 40 | 2 | – | Canada | MED | COG | DIS REN | QUAN | FOR |
| 41 | 1 | Q2 | Ethiopia | MED | COG | DIS REN | QUAN | FOR |
| 42 | 1 | – | Kazakhstan | CEX | COM | REN | QUAN | FOR |
| 43 | 1 | – | India | MED | ACT | REN | QUAN | CRI |
| 44 | 1 | – | Ireland | HUM | ACT | REN | QUAL | FOR |
| 45 | 0 | Q3 | Iran | MED | ACT | DIS REN | QUAN | CRI |